GILEAD SCIENCES, INC. for GILEAD SCIENCES INC
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 20, 2023 | $1,490,000 | Replaced |
| 4th Quarter - Amendment (this page) | Apr 14, 2023 | $1,490,000 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
International trade and protection of intellectual property; TRIPS Waiver; compulsory licensing and other IP issues in multiple countries.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL D BOYD | — |
| CHARLES M. CLAPTON | — |
| DAVID PULLIAM | — |
| GRACE RODDEN | — |
Health Issues HCR
Advocate on drug pricing proposals, including reconciliation legislation, and expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir). Reauthorization of the Prescription Drug User Fee Act and related issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TERESA BILL | — |
| BILL BODE | — |
| MICHAEL D BOYD | — |
| JENNIFER NIETO CAREY | — |
| CHARLES M. CLAPTON | — |
| ANNA GRIFFIN | — |
| DAVID PULLIAM | — |
| GRACE RODDEN | — |
Medicare/Medicaid MMM
Advocate on drug pricing proposals, including reconciliation legislation. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements including changes to best price.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TERESA BILL | — |
| BILL BODE | — |
| MICHAEL D BOYD | — |
| JENNIFER NIETO CAREY | — |
| CHARLES M. CLAPTON | — |
| ANNA GRIFFIN | — |
| DAVID PULLIAM | — |
| GRACE RODDEN | — |
Copyright/Patent/Trademark CPT
Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BILL BODE | — |
| JENNIFER NIETO CAREY | — |
| CHARLES M. CLAPTON | — |
| DAVID PULLIAM | — |
| GRACE RODDEN | — |
Budget/Appropriations BUD
Funding for Hepatitis C, HIV, oncology, and public health activities via appropriations. Advocate on drug pricing proposals, including reconciliation legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TERESA BILL | — |
| BILL BODE | — |
| JENNIFER NIETO CAREY | — |
| CHARLES M. CLAPTON | — |
| DAVID PULLIAM | — |
| GRACE RODDEN | — |
Taxation/Internal Revenue Code TAX
Legislative and regulatory proposals to change international and domestic corporate tax law and policy, including reconciliation legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M. CLAPTON | — |
| DAVID PULLIAM | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.